Amgen reported strong third-quarter earnings, surpassing expectations and raising its 2016 guidance, reflecting solid financial performance and improved operating margins. Positive pipeline developments, including promising data for Repatha and erenumab, indicate potential for future growth. While concerns about Enbrel's limited net price growth in 2017 and slow Repatha uptake exist, the overall outlook is positive.

[1]